GlassScriptPhysician profile
Thomas W Wells
NPI 1356301436
$2,639.41
in general payments reported to CMS, 2019-2025
21 companies · $972 in 2025
The $972 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $81.51 · 2022: $75.84 · 2023: $447 · 2024: $871 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $464.71 | 2019-2025 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $405.52 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $254.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $242.79 | 2024-2025 | Voquezna |
| Pfizer INC. | $185.65 | 2019-2024 | |
| Exact Sciences Corporation | $162.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $143.38 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.62 | 2025 | Jardiance |
| Stryker Corporation | $124.43 | 2024 | Aequalis Perform |
| Astrazeneca Pharmaceuticals LP | $95.88 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $76.63 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $76.09 | 2023-2025 | Freestyle Libre 3 |
| Lucid Diagnostics INC. | $59.43 | 2022 | |
| Sanofi-Aventis U.S. LLC | $49.15 | 2025 | |
| Dexcom, INC. | $41.47 | 2023-2024 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $23.66 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sumitomo Pharma America, INC. | $21.36 | 2025 | Gemtesa |
| Lundbeck LLC | $20.32 | 2025 | Vyepti |
| Xeris Pharmaceuticals, INC. | $18.87 | 2024 | Keveyis |
| Kowa Pharmaceuticals America, INC. | $18.06 | 2019 | |
| Medtronic Vascular, INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.